Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 174

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer

Open access
De Laere, Bram, Oeyen, Steffi, Mayrhofer, Markus, Whitington, Tom, van Dam, Pieter-Jan, Van Oyen, Peter, Ghysel, Christophe, Ampe, Jozef, Ost, Piet, Demey, Wim, Hoekx, Lucien, Schrijvers, Dirk, Brouwers, Barbara, Lybaert, Willem, Everaert, Els G., De Maeseneer, Daan, Strijbos, Michiel, Bols, Alain, Fransis, Karen, Beije, Nick, de Kruijff, Inge E., van Dam, Valerie, Brouwer, Anja, Goossens, Dirk, Heyrman, Lien, Van den Eynden, Gert G., Rutten, Annemie, Del Favero, Jurgen, Rantalainen, Mattias, Rajan, Prabhakar, Sleijfer, Stefan, Ullén, Anders, Yachnin, Jeffrey, Grönberg, Henrik, Van Laere, Steven J., Lindberg, Johan, Dirix, Luc Y. · 2019 · Clinical Cancer Research

Abstract

Purpose: To infer the prognostic value of simultaneous androgen receptor (AR) and TP53 profiling in liquid biopsies from patients with metastatic castration-resistant prostate cancer (mCRPC) starting a new line of AR signaling inhibitors (ARSi). Experimental Design: Between March 2014 and April 2017, we recruited patients with mCRPC (n = 168) prior to ARSi in a cohort study encompassing 10 European centers. Blood samples were collected for comprehensive profiling of CellSearch-enriched circulating tumor cells (CTC) and circulating tumor DNA (ctDNA). Targeted CTC RNA sequencing (RNA-seq) allowed the detection of eight AR splice variants (ARV). Low-pass whole-genome and targeted gene-body sequencing of AR and TP53 was applied to identify amplifications, loss of heterozygosity, mutations, and structural rearrangements in ctDNA. Clinical or radiologic progression-free survival (PFS) was estimated by Kaplan–Meier analysis, and independent associations were determined using multivariable Cox regression models. Results: Overall, no single AR perturbation remained associated with adverse prognosis after multivariable analysis. Instead, tumor burden estimates (CTC counts, ctDNA fraction, and visceral metastases) were significantly associated with PFS. TP53 inactivation harbored independent prognostic value [HR 1.88; 95% confidence interval (CI), 1.18–3.00; P = 0.008], and outperformed ARV expression and detection of genomic AR alterations. Using Cox coefficient analysis of clinical parameters and TP53 status, we identified three prognostic groups with differing PFS estimates (median, 14.7 vs. 7.51 vs. 2.62 months; P < 0.0001), which was validated in an independent mCRPC cohort (n = 202) starting first-line ARSi (median, 14.3 vs. 6.39 vs. 2.23 months; P < 0.0001). Conclusions: In an all-comer cohort, tumor burden estimates and TP53 outperform any AR perturbation to infer prognosis. See related commentary by Rebello et al., p. 1699

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-1943

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 174

Metadata

Authors
De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.-J., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., Brouwers, B., Lybaert, W., Everaert, E. G., De Maeseneer, D., Strijbos, M., Bols, A., Fransis, K., Beije, N., de Kruijff, I. E., van Dam, V., Brouwer, A., Goossens, D., Heyrman, L., Van den Eynden, G. G., Rutten, A., Del Favero, J., Rantalainen, M., Rajan, P., Sleijfer, S., Ullén, A., Yachnin, J., Grönberg, H., Van Laere, S. J., Lindberg, J., & Dirix, L. Y.
Venue
Clinical Cancer Research
Published
2019-03-15
Volume
25
Issue
6
Pages
1766-1773
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2892240038
Cited by
174
References
6
FWCI
14.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1943
The paper
De Laere, B., Oeyen, S., Mayrhofer, M., Whitington, T., van Dam, P.-J., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., Brouwers, B., Lybaert, W., Everaert, E. G., De Maeseneer, D., Strijbos, M., Bols, A., Fransis, K., . . . Dirix, L. Y. (2019). TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1943

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.